-
EP1283722
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1283722
| EP1283722 - COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-CD20 FOR THE TREATMENT OF B CELL LYMPHOMA [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.03.2010 Database last updated on 19.10.2024 | Most recent event Tooltip | 26.03.2010 | Application deemed to be withdrawn | published on 28.04.2010 [2010/17] | Applicant(s) | For all designated states Biogen Idec Inc. 14 Cambridge Center Cambridge, MA 02142 / US | [2009/14] |
| Former [2004/51] | For all designated states Biogen Idec Inc. 5200 Research Place San Diego, CA 92122 / US | ||
| Former [2003/08] | For all designated states Idec Pharmaceuticals Corporation 11011 Torreyana Road San Diego, CA 92121 / US | Inventor(s) | 01 /
HANNA, Nabil 14770 Avenida Insurgentes Rancho Santa Fe, CA 92067 / US | [2003/08] | Representative(s) | Adams, Harvey Vaughan John, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB | [N/P] |
| Former [2005/48] | Adams, Harvey Vaughan John, et al Mathys & Squire, 120 Holborn London EC1N 2SQ / GB | ||
| Former [2003/08] | Daniels, Jeffrey Nicholas, et al Page White & Farrer 54 Doughty Street London WC1N 2LS / GB | Application number, filing date | 01964666.0 | 02.04.2001 | [2003/08] | WO2001US10382 | Priority number, date | US20000193467P | 31.03.2000 Original published format: US 193467 P | [2003/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO0174388 | Date: | 11.10.2001 | Language: | EN | [2001/41] | Type: | A1 Application with search report | No.: | EP1283722 | Date: | 19.02.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.10.2001 takes the place of the publication of the European patent application. | [2003/08] | Search report(s) | International search report - published on: | EP | 11.10.2001 | Classification | IPC: | A61K39/395, A61P35/00, // (C07K16/24, 16:28), A61K39:395, A61K31:00 | [2003/08] | CPC: |
C07K16/244 (EP,US);
A61K39/395 (KR);
A61K39/39541 (EP,US);
A61K39/3955 (EP,US);
A61P35/00 (EP);
A61P35/02 (EP);
| C-Set: |
A61K39/39541, A61K2300/00 (EP,US);
A61K39/3955, A61K2300/00 (US,EP) | Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/08] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | KOMBINIERTE VERWENDUNG VON ANTI-ZYTOKIN-ANTIKÖRPERN ODER ANTAGONISTEN UND ANTI-CD20 ZUR BEHANDLUNG VON B-ZELL-LYMPHOMEN | [2003/08] | English: | COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-CD20 FOR THE TREATMENT OF B CELL LYMPHOMA | [2003/08] | French: | UTILISATION COMBINEE D'ANTICORPS OU D'ANTAGONISTES ANTI-CYTOKINE ET D'ANTI-CD20 POUR LE TRAITEMENT DU LYMPHOME B | [2003/08] | Entry into regional phase | 30.10.2002 | National basic fee paid | 30.10.2002 | Designation fee(s) paid | 30.10.2002 | Examination fee paid | Examination procedure | 26.10.2001 | Request for preliminary examination filed International Preliminary Examining Authority: US | 30.10.2002 | Examination requested [2003/08] | 22.06.2004 | Amendment by applicant (claims and/or description) | 26.04.2006 | Despatch of a communication from the examining division (Time limit: M06) | 06.11.2006 | Reply to a communication from the examining division | 04.01.2007 | Despatch of a communication from the examining division (Time limit: M06) | 16.07.2007 | Reply to a communication from the examining division | 12.02.2008 | Despatch of a communication from the examining division (Time limit: M07) | 02.09.2008 | Reply to a communication from the examining division | 31.10.2009 | Application deemed to be withdrawn, date of legal effect [2010/17] | 08.12.2009 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2010/17] | Fees paid | Renewal fee | 14.04.2003 | Renewal fee patent year 03 | 15.04.2004 | Renewal fee patent year 04 | 20.04.2005 | Renewal fee patent year 05 | 26.04.2006 | Renewal fee patent year 06 | 27.04.2007 | Renewal fee patent year 07 | 25.04.2008 | Renewal fee patent year 08 | Penalty fee | Additional fee for renewal fee | 30.04.2009 | 09 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]DE29512719U (SABAT ROBERT [DE], et al) [X] 72,73 * page 2, paragraph 1 * * page 3, paragraph 5 * [Y] 1-14,18-47,50,52-56,58-71,74-86; | [XY]WO9404180 (SCHERING CORP [US]) [X] 72,73 * abstract * * page 1, line 9 - page 2, line 9 * * claims 1-11 * [Y] 1-14,18-47,50,52-56,58-71,74-86; | [Y] - CZUCZMAN M S ET AL, "Treatment of patients with low-grade B-cell Lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy", JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, (199901), vol. 17, no. 1, pages 268 - 276, XP000952705 [Y] 1-14,18-47,50,52-56,58-71,74-86 * abstract * * page 268, column 1, line 1 - page 269, column 2, paragraph 2 * * page 270, column 1, paragraph 3 - column 2, paragraph 3 * * page 275, column 2, paragraph 2 * | [Y] - DEMIDEM AICHA ET AL, "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (1997), Database accession no. PREV199799709997, XP002176012 [Y] 29-47,50,52-56,58-71,74-86 * abstract * | [ ] - CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, (1997), vol. 12, no. 3, ISSN 1084-9785, pages 177 - 186 | [Y] - BUSKE C ET AL, "Monoclonal antibody therapy for b cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (1999), vol. 35, no. 4, ISSN 0959-8049, pages 549 - 557, XP001010018 [Y] 29-47,50,52-56,58-71,74-86 * abstract * * page 550, column 1, paragraph 4 - page 553, column 2, paragraph 1 * * page 555, column 1, paragraph L * DOI: http://dx.doi.org/10.1016/S0959-8049(98)00420-1 | [A] - CORTES J KURZROCK R, "Interleukin-10 in non-Hodgkin's lymphoma", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, (199707), vol. 26, no. 3/4, ISSN 1042-8194, pages 251 - 259, XP001020774 [A] 1-14,18-47,50,52-56,58-86 * the whole document * | Examination | - DEMIDEM A. ET AL, "ENDOGENOUS IL-10 IS A PROTECTIVE FACTOR IN DRUG RESISTANT AIDS-RELATED LYMPHOMA (ARL)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, (19950318), vol. 36, page 323, XP001009556 | - ALAS ET AL, "Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin's Lymphoma to apoptosis", CLINICAL CANCER RESEARCH, (200103), vol. 7, pages 709 - 723 |